Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis

被引:153
作者
Chandran, Vinod
Bhella, Sita
Schentag, Catherine
Gladman, Dafna D.
机构
[1] Univ Hlth Network, Toronto Western Hosp, Psoriat Arthrit Program, Toronto, ON, Canada
[2] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
关键词
D O I
10.1136/ard.2006.065763
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fatigue is an important symptom in psoriatic arthritis ( PsA). Aim: To determine the reliability and validity of the Functional Assessment of Chronic Illness Therapy- Fatigue ( FACIT fatigue) Scale in PsA. Methods: Consecutive patients attending the PsA clinic were assessed with the FACIT fatigue Scale twice, 1 week apart. Patients were assessed clinically according to a standardised PsA clinic protocol. Internal consistency of the 13 items on the FACIT fatigue questionnaire was measured using Cronbach's alpha; test - retest reliability by the intraclass correlation coefficient ( ICC), and validity by the correlation of the FACIT fatigue results with other fatigue measures and disease characteristics. Results: 135 patients ( 80 men and 55 women, mean ( SD) age 52 ( 13) years, mean ( SD) disease duration 17 ( 10) years) participated. The mean FACIT fatigue score was 35.8 ( 12.4). Cronbach's a was 0.96. Repeat questionnaires were returned by 54% of patients. No difference in disease characteristics was observed between those who did and did not return the questionnaires. The ICC for first and repeat FACIT fatigue scores was 0.95. The correlation between the FACIT fatigue and modified Fatigue Severity Score was 20.79 ( 95% CI -0.85 to -0.72). FACIT fatigue scores were lower in patients with overwhelming fatigue and fibromyalgia than in those without ( p < 0.001). The FACIT fatigue was correlated with the actively inflamed joint count ( - 0.43, 95% CI - 0.56 to - 0.28, p, 0.001), but not with the clinically damaged joint count ( -0.06, 95% CI -0.23 to 0.11, p = 0.51). Conclusion: The FACIT fatigue results were reproducible, and correlated with other fatigue measures as well as with disease activity in patients with PsA. Therefore, the FACIT fatigue is a reliable and valid instrument to measure fatigue in PsA.
引用
收藏
页码:936 / 939
页数:4
相关论文
共 40 条
  • [1] BELZA BL, 1993, NURS RES, V42, P93
  • [2] Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
    Calin, A
    Dijkmans, BAC
    Emery, P
    Hakala, M
    Kalden, J
    Leirisalo-Repo, M
    Mola, EM
    Salvarani, C
    Sanmartí, R
    Sany, J
    Sibilia, J
    Sieper, J
    van der Linden, S
    Veys, E
    Appel, AM
    Fatenejad, S
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) : 1594 - 1600
  • [3] Cella D, 2005, J RHEUMATOL, V32, P811
  • [4] Fatigue in cancer patients compared with fatigue in the general United States population
    Cella, D
    Lai, JS
    Chang, CH
    Peterman, A
    Slavin, M
    [J]. CANCER, 2002, 94 (02) : 528 - 538
  • [5] Cella D, 1997, MANUAL FUNCTIONAL AS
  • [6] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [7] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Cohen, Stanley B.
    Emery, Paul
    Greenwald, Maria W.
    Dougados, Maxime
    Furie, Richard A.
    Genovese, Mark C.
    Keystone, Edward C.
    Loveless, James E.
    Burmester, Gerd-Ruediger
    Cravets, Matthew W.
    Hessey, Eva W.
    Shaw, Timothy
    Totoritis, Mark C.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
  • [8] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
    Emery, P
    Fleischmann, R
    Filipowicz-Sosnowska, A
    Schechtman, J
    Szczepanski, L
    Kavanaugh, A
    Racewicz, AJ
    Van Vollenhoven, RF
    Li, NF
    Agarwal, S
    Hessey, EW
    Shaw, TM
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1390 - 1400
  • [9] THE IMPACT OF FATIGUE ON PATIENTS WITH MULTIPLE-SCLEROSIS
    FISK, JD
    PONTEFRACT, A
    RITVO, PG
    ARCHIBALD, CJ
    MURRAY, TJ
    [J]. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1994, 21 (01) : 9 - 14
  • [10] FREAL JE, 1984, ARCH PHYS MED REHAB, V65, P135